What is Veraxa Biotech AG Ordinary Shares?
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 147.06M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.